Neuropsychotherapeutics
Author(s)
Bibliographic Information
Neuropsychotherapeutics
(Advances in pharmacology / edited by Silvio Garattini [and] Parkhurst A. Shore, v. 86)
Academic Press, an imprint of Elsevier, 2019
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Description and Table of Contents
Description
Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.
Table of Contents
1. GPCR drug discovery-moving beyond the orthosteric to the allosteric domainChristian C. Felder2. Lipid rafts in psychiatryNathan H. Wray and Mark M. Rasenick3. Rapid-acting antidepressantsJeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu and Jodi L. Smith4. mGlu2/3 receptor antagonistsShigeyuki Chaki5. Nitric oxide: Antidepressant mechanisms and inflammationMehdi Ghasemi6. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B. Teal, Robert W. Gould, Andrew S. Felts and Carrie K. Jones7. Medications development for food-based and drug use disordersFernando B. de Moura, Stephen J. Kohut and Jack Bergman8. Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic researchErik Z. Woody, Kurt Leroy Hoffman and Henry Szechtman9. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A. Svensson, Junliang Hao and Robert F. Bruns
by "Nielsen BookData"